GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MEI Pharma Inc (FRA:MMI0) » Definitions » Other Liabilities for Banks

MEI Pharma (FRA:MMI0) Other Liabilities for Banks


View and export this data going back to 2013. Start your Free Trial

What is MEI Pharma Other Liabilities for Banks?

Other Liabilities (Bank) only applies to banks.


MEI Pharma (FRA:MMI0) Business Description

Industry
Traded in Other Exchanges
Address
11455 El Camino Real, Suite 250, San Diego, CA, USA, 92130
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.